Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

CD73 inhibitor

DRUG CLASS:

CD73 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	durvalumab + MEDI9447 Sensitive: C2 – Inclusion Criteria durvalumab + MEDI9447 Sensitive : C2	durvalumab + MEDI9447 Sensitive: C2 – Inclusion Criteria durvalumab + MEDI9447 Sensitive : C2
EGFR exon 18 deletion	Non Small Cell Lung Cancer	EGFR exon 18 deletion	Non Small Cell Lung Cancer	osimertinib + MEDI9447 Sensitive: C3 – Early Trials osimertinib + MEDI9447 Sensitive : C3	osimertinib + MEDI9447 Sensitive: C3 – Early Trials osimertinib + MEDI9447 Sensitive : C3
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	osimertinib + MEDI9447 Sensitive: C3 – Early Trials osimertinib + MEDI9447 Sensitive : C3	osimertinib + MEDI9447 Sensitive: C3 – Early Trials osimertinib + MEDI9447 Sensitive : C3
CD73 expression	Solid Tumor	CD73 expression	Solid Tumor	atezolizumab + TJD5 Sensitive: C3 – Early Trials atezolizumab + TJD5 Sensitive : C3	atezolizumab + TJD5 Sensitive: C3 – Early Trials atezolizumab + TJD5 Sensitive : C3
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib + MEDI9447 Sensitive: C3 – Early Trials osimertinib + MEDI9447 Sensitive : C3	osimertinib + MEDI9447 Sensitive: C3 – Early Trials osimertinib + MEDI9447 Sensitive : C3
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	MEDI9447 Sensitive: C3 – Early Trials MEDI9447 Sensitive : C3	MEDI9447 Sensitive: C3 – Early Trials MEDI9447 Sensitive : C3
ALK wild-type + NT5E overexpression + PD-L1 expression	Non Small Cell Lung Cancer	ALK wild-type + NT5E overexpression + PD-L1 expression	Non Small Cell Lung Cancer	toripalimab-tpzi + TJD5 Sensitive: C3 – Early Trials toripalimab-tpzi + TJD5 Sensitive : C3	toripalimab-tpzi + TJD5 Sensitive: C3 – Early Trials toripalimab-tpzi + TJD5 Sensitive : C3
EGFR wild-type + ALK wild-type + NT5E overexpression + PD-L1 expression	Non Small Cell Lung Cancer	EGFR wild-type + ALK wild-type + NT5E overexpression + PD-L1 expression	Non Small Cell Lung Cancer	toripalimab-tpzi + TJD5 Sensitive: C3 – Early Trials toripalimab-tpzi + TJD5 Sensitive : C3	toripalimab-tpzi + TJD5 Sensitive: C3 – Early Trials toripalimab-tpzi + TJD5 Sensitive : C3
CD73 elevation	Triple Negative Breast Cancer	CD73 elevation	Triple Negative Breast Cancer	durvalumab + MEDI9447 Resistant: C3 – Early Trials durvalumab + MEDI9447 Resistant : C3	durvalumab + MEDI9447 Resistant: C3 – Early Trials durvalumab + MEDI9447 Resistant : C3
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	PD-L1 inhibitor + CD73 inhibitor Sensitive: D – Preclinical PD-L1 inhibitor + CD73 inhibitor Sensitive : D	PD-L1 inhibitor + CD73 inhibitor Sensitive: D – Preclinical PD-L1 inhibitor + CD73 inhibitor Sensitive : D
HOXA9 overexpression + MEIS1 overexpression	Acute Myelogenous Leukemia	HOXA9 overexpression + MEIS1 overexpression	Acute Myelogenous Leukemia	INT-1B3 Sensitive: D – Preclinical INT-1B3 Sensitive : D	INT-1B3 Sensitive: D – Preclinical INT-1B3 Sensitive : D